Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Faisal Azam

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Saudi Journal of Biological Sciences|January 10, 2022
The association between two genetic polymorphisms in <i>ITGB3</i> and increase risk of venous thromboembolism in cancer patients in Eastern Province of Saudi ArabiaAsma Y Alsulaim, Faisal Azam, Tunny Sebastian, et al.
Cureus|July 8, 2022
Metastatic Type II Papillary Renal Cell Carcinoma With Recurrent Complete Responses to Sunitinib: A Case Report With a Literature ReviewBayan H Al Ashour, Faisal Azam, Fahad Ibnshamsah, et al.
Cureus|September 9, 2024
Eligibility Criteria for Different Platinum-Based Chemotherapy Regimens in Metastatic Urothelial CarcinomaFaisal Azam, Hulayel Alharbi, Abdulraheem Alshangiti, et al.
Scientific Reports|October 15, 2024
Dysgerminomas: germ cell tumors exhibit high expression of PD-L1 and associated with high TILs and good prognosisKholoud Alwosaibai, Zainab Ibrahim Alruwaii, Miral Mashhour, et al.
BMC Cancer|January 5, 2023
PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markersKholoud Alwosaibai, Salmah Aalmri, Miral Mashhour, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 18, 2025
Assessing Response Durability and Survival After Second-Line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk ModelSamer Salah, Katsuhiro Ito, Yuki Kita, et al.
BMC Urology|December 22, 2025
Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi ArabiaShouki Bazarbashi, Ahmed S Abdelmotal, Tarek Arabi, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Saudi Journal of Biological Sciences|January 10, 2022
The association between two genetic polymorphisms in <i>ITGB3</i> and increase risk of venous thromboembolism in cancer patients in Eastern Province of Saudi ArabiaAsma Y Alsulaim, Faisal Azam, Tunny Sebastian, et al.
Cureus|July 8, 2022
Metastatic Type II Papillary Renal Cell Carcinoma With Recurrent Complete Responses to Sunitinib: A Case Report With a Literature ReviewBayan H Al Ashour, Faisal Azam, Fahad Ibnshamsah, et al.
Cureus|September 9, 2024
Eligibility Criteria for Different Platinum-Based Chemotherapy Regimens in Metastatic Urothelial CarcinomaFaisal Azam, Hulayel Alharbi, Abdulraheem Alshangiti, et al.
Scientific Reports|October 15, 2024
Dysgerminomas: germ cell tumors exhibit high expression of PD-L1 and associated with high TILs and good prognosisKholoud Alwosaibai, Zainab Ibrahim Alruwaii, Miral Mashhour, et al.
BMC Cancer|January 5, 2023
PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markersKholoud Alwosaibai, Salmah Aalmri, Miral Mashhour, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 18, 2025
Assessing Response Durability and Survival After Second-Line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk ModelSamer Salah, Katsuhiro Ito, Yuki Kita, et al.
BMC Urology|December 22, 2025
Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi ArabiaShouki Bazarbashi, Ahmed S Abdelmotal, Tarek Arabi, et al.
Pageof 3